CN109432388A - The composition and its application in terms of bony articulation health of a kind of probiotics and aminoglucose hydrochloride - Google Patents
The composition and its application in terms of bony articulation health of a kind of probiotics and aminoglucose hydrochloride Download PDFInfo
- Publication number
- CN109432388A CN109432388A CN201811594602.9A CN201811594602A CN109432388A CN 109432388 A CN109432388 A CN 109432388A CN 201811594602 A CN201811594602 A CN 201811594602A CN 109432388 A CN109432388 A CN 109432388A
- Authority
- CN
- China
- Prior art keywords
- composition
- calcium
- weight
- group
- parts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 67
- 230000036541 health Effects 0.000 title claims abstract description 25
- CHVZQMAANSUXJU-JJKGCWMISA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanamide;hydrochloride Chemical compound Cl.NC(=O)[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO CHVZQMAANSUXJU-JJKGCWMISA-N 0.000 title claims abstract description 23
- 239000006041 probiotic Substances 0.000 title claims abstract description 19
- 235000018291 probiotics Nutrition 0.000 title claims abstract description 19
- 230000037182 bone density Effects 0.000 claims abstract description 33
- 229910052500 inorganic mineral Inorganic materials 0.000 claims abstract description 23
- 239000011707 mineral Substances 0.000 claims abstract description 23
- 150000003839 salts Chemical class 0.000 claims abstract description 16
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 claims abstract description 15
- 229940009289 bifidobacterium lactis Drugs 0.000 claims abstract description 15
- 235000013305 food Nutrition 0.000 claims abstract description 15
- 241001608472 Bifidobacterium longum Species 0.000 claims abstract description 14
- 229940009291 bifidobacterium longum Drugs 0.000 claims abstract description 14
- 239000005018 casein Substances 0.000 claims abstract description 13
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims abstract description 13
- 235000021240 caseins Nutrition 0.000 claims abstract description 13
- 229940079593 drug Drugs 0.000 claims abstract description 13
- 239000003814 drug Substances 0.000 claims abstract description 13
- 108010001441 Phosphopeptides Proteins 0.000 claims abstract description 12
- 229920001542 oligosaccharide Polymers 0.000 claims abstract description 11
- 150000002482 oligosaccharides Chemical class 0.000 claims abstract description 11
- 241000186660 Lactobacillus Species 0.000 claims abstract description 10
- 229940039696 lactobacillus Drugs 0.000 claims abstract description 10
- 238000002360 preparation method Methods 0.000 claims description 31
- 239000000463 material Substances 0.000 claims description 22
- 230000003185 calcium uptake Effects 0.000 claims description 19
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- 239000005913 Maltodextrin Substances 0.000 claims description 5
- 229920002774 Maltodextrin Polymers 0.000 claims description 5
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 claims description 5
- 229940035034 maltodextrin Drugs 0.000 claims description 5
- 235000019359 magnesium stearate Nutrition 0.000 claims description 4
- 229920002472 Starch Polymers 0.000 claims description 3
- 235000021255 galacto-oligosaccharides Nutrition 0.000 claims description 3
- 150000003271 galactooligosaccharides Chemical class 0.000 claims description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 3
- 239000008107 starch Substances 0.000 claims description 3
- 235000019698 starch Nutrition 0.000 claims description 3
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 claims description 2
- 229960002442 glucosamine Drugs 0.000 claims description 2
- 239000008103 glucose Substances 0.000 claims description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 claims 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims 1
- 235000001727 glucose Nutrition 0.000 claims 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 abstract description 71
- 239000011575 calcium Substances 0.000 abstract description 71
- 229910052791 calcium Inorganic materials 0.000 abstract description 71
- 229960005069 calcium Drugs 0.000 description 70
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical group [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 34
- 241000700159 Rattus Species 0.000 description 32
- 210000000988 bone and bone Anatomy 0.000 description 28
- 235000010755 mineral Nutrition 0.000 description 21
- 229910000019 calcium carbonate Inorganic materials 0.000 description 17
- 229960003563 calcium carbonate Drugs 0.000 description 17
- 235000010216 calcium carbonate Nutrition 0.000 description 17
- 238000002474 experimental method Methods 0.000 description 16
- 210000000689 upper leg Anatomy 0.000 description 13
- 244000005700 microbiome Species 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- 239000011782 vitamin Substances 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 208000001132 Osteoporosis Diseases 0.000 description 11
- 235000019786 weight gain Nutrition 0.000 description 11
- 230000004584 weight gain Effects 0.000 description 11
- 229940088594 vitamin Drugs 0.000 description 10
- 229930003231 vitamin Natural products 0.000 description 10
- 235000013343 vitamin Nutrition 0.000 description 10
- 150000003722 vitamin derivatives Chemical class 0.000 description 10
- 239000008367 deionised water Substances 0.000 description 9
- 229910021641 deionized water Inorganic materials 0.000 description 9
- 241000196324 Embryophyta Species 0.000 description 8
- 238000010521 absorption reaction Methods 0.000 description 8
- 235000021053 average weight gain Nutrition 0.000 description 7
- 238000011049 filling Methods 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 230000037396 body weight Effects 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- 239000002552 dosage form Substances 0.000 description 6
- 239000013641 positive control Substances 0.000 description 6
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 6
- 240000006024 Lactobacillus plantarum Species 0.000 description 5
- 235000013965 Lactobacillus plantarum Nutrition 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 229940072205 lactobacillus plantarum Drugs 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- GZCGUPFRVQAUEE-SLPGGIOYSA-N aldehydo-D-glucose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-SLPGGIOYSA-N 0.000 description 4
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 210000001672 ovary Anatomy 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 241000186000 Bifidobacterium Species 0.000 description 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000003054 hormonal effect Effects 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
- PMYDPQQPEAYXKD-UHFFFAOYSA-N 3-hydroxy-n-naphthalen-2-ylnaphthalene-2-carboxamide Chemical compound C1=CC=CC2=CC(NC(=O)C3=CC4=CC=CC=C4C=C3O)=CC=C21 PMYDPQQPEAYXKD-UHFFFAOYSA-N 0.000 description 2
- WIGIZIANZCJQQY-UHFFFAOYSA-N 4-ethyl-3-methyl-N-[2-[4-[[[(4-methylcyclohexyl)amino]-oxomethyl]sulfamoyl]phenyl]ethyl]-5-oxo-2H-pyrrole-1-carboxamide Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCC(C)CC2)C=C1 WIGIZIANZCJQQY-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 208000010392 Bone Fractures Diseases 0.000 description 2
- 206010017076 Fracture Diseases 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- CPLXHLVBOLITMK-UHFFFAOYSA-N Magnesium oxide Chemical compound [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 2
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 2
- 229930003316 Vitamin D Natural products 0.000 description 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 229930003448 Vitamin K Natural products 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000002146 bilateral effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 2
- 229960002079 calcium pantothenate Drugs 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 238000013329 compounding Methods 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 229960000304 folic acid Drugs 0.000 description 2
- 235000019152 folic acid Nutrition 0.000 description 2
- 239000011724 folic acid Substances 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- -1 hydroxypropyl Chemical group 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 239000011656 manganese carbonate Substances 0.000 description 2
- 235000006748 manganese carbonate Nutrition 0.000 description 2
- 229940093474 manganese carbonate Drugs 0.000 description 2
- 229910000016 manganese(II) carbonate Inorganic materials 0.000 description 2
- XMWCXZJXESXBBY-UHFFFAOYSA-L manganese(ii) carbonate Chemical compound [Mn+2].[O-]C([O-])=O XMWCXZJXESXBBY-UHFFFAOYSA-L 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 2
- 235000019796 monopotassium phosphate Nutrition 0.000 description 2
- 229960003512 nicotinic acid Drugs 0.000 description 2
- 235000001968 nicotinic acid Nutrition 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 2
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 2
- 239000011655 sodium selenate Substances 0.000 description 2
- 235000018716 sodium selenate Nutrition 0.000 description 2
- 229960001881 sodium selenate Drugs 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 235000019155 vitamin A Nutrition 0.000 description 2
- 239000011719 vitamin A Substances 0.000 description 2
- 235000019166 vitamin D Nutrition 0.000 description 2
- 239000011710 vitamin D Substances 0.000 description 2
- 150000003710 vitamin D derivatives Chemical class 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 235000019168 vitamin K Nutrition 0.000 description 2
- 239000011712 vitamin K Substances 0.000 description 2
- 150000003721 vitamin K derivatives Chemical class 0.000 description 2
- 229940045997 vitamin a Drugs 0.000 description 2
- 229940046008 vitamin d Drugs 0.000 description 2
- 229940046010 vitamin k Drugs 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- PQMFVUNERGGBPG-UHFFFAOYSA-N (6-bromopyridin-2-yl)hydrazine Chemical compound NNC1=CC=CC(Br)=N1 PQMFVUNERGGBPG-UHFFFAOYSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- UBDZFAGVPPMTIT-UHFFFAOYSA-N 2-aminoguanidine;hydron;chloride Chemical compound [Cl-].NC(N)=N[NH3+] UBDZFAGVPPMTIT-UHFFFAOYSA-N 0.000 description 1
- 108010011619 6-Phytase Proteins 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 240000004307 Citrus medica Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 1
- 206010020100 Hip fracture Diseases 0.000 description 1
- 235000002710 Ilex cornuta Nutrition 0.000 description 1
- 241001310146 Ilex cornuta Species 0.000 description 1
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 description 1
- 235000010326 Osmanthus heterophyllus Nutrition 0.000 description 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- IMQLKJBTEOYOSI-UHFFFAOYSA-N Phytic acid Natural products OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 239000004115 Sodium Silicate Substances 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- FMRLDPWIRHBCCC-UHFFFAOYSA-L Zinc carbonate Chemical compound [Zn+2].[O-]C([O-])=O FMRLDPWIRHBCCC-UHFFFAOYSA-L 0.000 description 1
- CANRESZKMUPMAE-UHFFFAOYSA-L Zinc lactate Chemical compound [Zn+2].CC(O)C([O-])=O.CC(O)C([O-])=O CANRESZKMUPMAE-UHFFFAOYSA-L 0.000 description 1
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 1
- WKNIDMJWLWUOMZ-UHFFFAOYSA-N [K].[Cr] Chemical compound [K].[Cr] WKNIDMJWLWUOMZ-UHFFFAOYSA-N 0.000 description 1
- RBCOAYPERRCEFY-UHFFFAOYSA-N [K].[Fe].[Zn].[Cu] Chemical compound [K].[Fe].[Zn].[Cu] RBCOAYPERRCEFY-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- UNTBPXHCXVWYOI-UHFFFAOYSA-O azanium;oxido(dioxo)vanadium Chemical compound [NH4+].[O-][V](=O)=O UNTBPXHCXVWYOI-UHFFFAOYSA-O 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008468 bone growth Effects 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 239000004227 calcium gluconate Substances 0.000 description 1
- 235000013927 calcium gluconate Nutrition 0.000 description 1
- 229960004494 calcium gluconate Drugs 0.000 description 1
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 1
- 239000001527 calcium lactate Substances 0.000 description 1
- 235000011086 calcium lactate Nutrition 0.000 description 1
- 229960002401 calcium lactate Drugs 0.000 description 1
- 230000003913 calcium metabolism Effects 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- QSWDMMVNRMROPK-UHFFFAOYSA-K chromium(3+) trichloride Chemical class [Cl-].[Cl-].[Cl-].[Cr+3] QSWDMMVNRMROPK-UHFFFAOYSA-K 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229940116318 copper carbonate Drugs 0.000 description 1
- JZCCFEFSEZPSOG-UHFFFAOYSA-L copper(II) sulfate pentahydrate Chemical compound O.O.O.O.O.[Cu+2].[O-]S([O-])(=O)=O JZCCFEFSEZPSOG-UHFFFAOYSA-L 0.000 description 1
- GEZOTWYUIKXWOA-UHFFFAOYSA-L copper;carbonate Chemical compound [Cu+2].[O-]C([O-])=O GEZOTWYUIKXWOA-UHFFFAOYSA-L 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 229960003943 hypromellose Drugs 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229960003284 iron Drugs 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- 229940091250 magnesium supplement Drugs 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 229910000008 nickel(II) carbonate Inorganic materials 0.000 description 1
- ZULUUIKRFGGGTL-UHFFFAOYSA-L nickel(ii) carbonate Chemical compound [Ni+2].[O-]C([O-])=O ZULUUIKRFGGGTL-UHFFFAOYSA-L 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 229940085127 phytase Drugs 0.000 description 1
- 229940068041 phytic acid Drugs 0.000 description 1
- 239000000467 phytic acid Substances 0.000 description 1
- 235000002949 phytic acid Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- OTYBMLCTZGSZBG-UHFFFAOYSA-L potassium sulfate Chemical compound [K+].[K+].[O-]S([O-])(=O)=O OTYBMLCTZGSZBG-UHFFFAOYSA-L 0.000 description 1
- 229910052939 potassium sulfate Inorganic materials 0.000 description 1
- 235000011151 potassium sulphates Nutrition 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 108010048734 sclerotin Proteins 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 229940091258 selenium supplement Drugs 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 235000021391 short chain fatty acids Nutrition 0.000 description 1
- 150000004666 short chain fatty acids Chemical class 0.000 description 1
- 239000011775 sodium fluoride Substances 0.000 description 1
- 235000013024 sodium fluoride Nutrition 0.000 description 1
- 235000019795 sodium metasilicate Nutrition 0.000 description 1
- NTHWMYGWWRZVTN-UHFFFAOYSA-N sodium silicate Chemical compound [Na+].[Na+].[O-][Si]([O-])=O NTHWMYGWWRZVTN-UHFFFAOYSA-N 0.000 description 1
- 229910052911 sodium silicate Inorganic materials 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-N sodium;5-ethyl-5-pentan-2-yl-1,3-diazinane-2,4,6-trione Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)NC1=O QGMRQYFBGABWDR-UHFFFAOYSA-N 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 206010041569 spinal fracture Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 229960000344 thiamine hydrochloride Drugs 0.000 description 1
- 235000019190 thiamine hydrochloride Nutrition 0.000 description 1
- 239000011747 thiamine hydrochloride Substances 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 238000011121 vaginal smear Methods 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011667 zinc carbonate Substances 0.000 description 1
- 235000004416 zinc carbonate Nutrition 0.000 description 1
- 229910000010 zinc carbonate Inorganic materials 0.000 description 1
- 239000011576 zinc lactate Substances 0.000 description 1
- 235000000193 zinc lactate Nutrition 0.000 description 1
- 229940050168 zinc lactate Drugs 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- 235000014692 zinc oxide Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The present invention provides the compositions and its application in terms of bony articulation health of a kind of probiotics and aminoglucose hydrochloride, are related to probiotics technical field.The composition of probiotics of the present invention and aminoglucose hydrochloride comprises the following components in parts by weight: 1~5 part of plant lactobacillus LP-Onlly, 1~5 part of bifidobacterium lactis BI516,1~5 part of bifidobacterium longum BL88-Onlly, 20~40 parts of aminoglucose hydrochloride, 20~40 parts of newborn mineral salt, 1~10 part and 1~10 part of casein phosphopeptide of oligosaccharide.The composition of probiotics of the present invention and aminoglucose hydrochloride has the function of increasing bone density, promotes calcium absorptivity, can be used for making corresponding food or drug or health care product.
Description
Technical field
The invention belongs to probiotics technical fields, and in particular to the composition of a kind of probiotics and aminoglucose hydrochloride and
Its application in terms of bony articulation health.
Background technique
Osteoporosis (osteoporosis, OP) is one kind characterized by Low BMD and bone tissue Microstructure Fracture, is caused
Sclerotin brittleness increases and is easy to the systemic bone metabolic disease fractured, and is common in the elderly, but each period at age can fall ill.
" osteoporosis prevents and treats Chinese white paper " points out that Chinese at least 69,440,000 people suffer from osteoporosis, there is the low bone of 2.1 hundred million people
Amount, there are the risk of osteoporosis, 70%~80% person in middle and old age fracture be because of osteoporosis caused by, wherein annual new hair
For vertebral fracture there are about 1,810,000 people, Hip Fracture case is 230,000.The study found that 55~65 years old incidence of osteoporosis is 54%
~71%；The elderly illness rate male is 60.72%, and women 90.47%.With the arrival of aging society, osteoporosis
Disease has become the high-incidence disease for threatening middle-aged and the old's health.
Bone density refers to the bone mineral content of unit volume, is an important symbol of bone mass.Mineral deposit
More, bone density is bigger, and bone is more solid.Bone density is the main standard of diagnosis of osteoporosis, World Health Organization's definition
2.5 standard deviations of adult female's bone density subaverage are osteoporosis.
For osteoporosis, common commercially available calcium complement agent is calcium carbonate, calcium gluconate and calcium lactate etc., these calcium
The problem of replenishers can only provide the minerals based on calcium, not can solve bone calcium loss and promote bone mineralising, but also cannot be true
Surely no absorption and absorptivity reach how many.
Summary of the invention
In view of this, the purpose of the present invention is to provide the composition of a kind of probiotics and aminoglucose hydrochloride and its
Application in terms of bony articulation health, the absorption that bone density can be increased, replenish the calcium and promote calcium, for safeguarding articulation health.
In order to achieve the above-mentioned object of the invention, the present invention the following technical schemes are provided:
The present invention provides the compositions of a kind of probiotics and aminoglucose hydrochloride, comprise the following components in parts by weight:
1~5 part of plant lactobacillus LP-Onlly, 1~5 part of bifidobacterium lactis BI516,1~5 part of bifidobacterium longum BL88-Onlly,
20~40 parts of aminoglucose hydrochloride, 20~40 parts of newborn mineral salt, 1~10 part and 1~10 part of casein phosphopeptide of oligosaccharide.
Preferably, the oligosaccharide includes: in oligofructose, xylo-oligosaccharide, oligoisomaltose and galactooligosaccharide
One or more mixing.
It preferably, further include auxiliary material in the composition, the parts by weight of the auxiliary material are 2~9 parts.
Preferably, the auxiliary material includes: that maltodextrin, starch, lactose, DEXTROSE ANHYDROUS, magnesium stearate and hydroxypropyl first are fine
Tie up one of element or a variety of mixing.
The present invention also provides application of the above-mentioned composition in the food that preparation increases bone density.
The present invention also provides application of the above-mentioned composition in the drug that preparation increases bone density.
The present invention also provides application of the above-mentioned composition in the health care product that preparation increases bone density.
The present invention also provides application of the above-mentioned composition in the food that preparation promotes calcium uptake.
The present invention also provides application of the above-mentioned composition in the drug that preparation promotes calcium uptake.
The present invention also provides application of the above-mentioned composition in the health care product that preparation promotes calcium uptake.
The present invention provides the compositions of a kind of probiotics and aminoglucose hydrochloride, using lactobacillus plantarum LP-
Onlly, bifidobacterium lactis BI516, bifidobacterium longum BL88-Onlly, aminoglucose hydrochloride, newborn mineral salt, oligosaccharide, junket
Protein phosphatase polypeptide and auxiliary material compounding are made, and have the probiotics of positive facilitation by the absorption to mineral matter element, promote
The synthesis of vitamin and phytase, so that phytic acid be inhibited to act on, released mineral matter while, promotes the absorption of calcium；In addition probiotics
It also can produce short chain fatty acids, the absorption of calcium improved by its dissolution.In composition of the present invention, aminoguanidine hydrochloride is utilized
Glucose protects cartilage, maintenance articulation health, and newborn mineral salt is for supplement calcium and the important nutrient of bone growth, benefit
Promote the absorption of calcium with probiotics, be aided with the ingredients such as casein phosphopeptide again after three's compounding, can be used for developing safely and effectively
With maintenance articulation health, increase bone density, the food for the absorption replenished the calcium and promote calcium or drug or health care product.
Preservation explanation
Lactobacillus plantarum (Lactobacillusplantarum), strain number LP-Onlly, December 06 in 2004
Day is deposited in China Committee for Culture Collection of Microorganisms's common micro-organisms center, and address is BeiChen West Road, Chaoyang District, BeiJing City
No. 1 institute 3, Institute of Microorganism, Academia Sinica, biological deposits number is CGMCC No.1258.
Bifidobacterium lactis (Bifidobacterium lactis), strain number BI516 were protected on 01 04th, 2016
China Committee for Culture Collection of Microorganisms's common micro-organisms center is ensconced, specific address is BeiChen West Road, Chaoyang District, BeiJing City
No. 1 institute 3, Institute of Microorganism, Academia Sinica, biological deposits number is CGMCC No.11959.
Bifidobacterium longum (Bifidobacterium longum), strain number BL88-Onlly, in 07 month 2007
It is deposited within 13rd China Committee for Culture Collection of Microorganisms's common micro-organisms center, address is Chaoyang District, Beijing City North Star west
The institute 3 of road 1, Institute of Microorganism, Academia Sinica, biological deposits number is CGMCC No.2107.
Specific embodiment
The present invention provides the compositions of a kind of probiotics and aminoglucose hydrochloride, comprise the following components in parts by weight:
1~5 part of plant lactobacillus LP-Onlly, 1~5 part of bifidobacterium lactis BI516,1~5 part of bifidobacterium longum BL88-Onlly,
20~40 parts of aminoglucose hydrochloride, 20~40 parts of newborn mineral salt, 1~10 part and 1~10 part of casein phosphopeptide of oligosaccharide.
In composition of the present invention, including plant lactobacillus LP-Onlly, the plant lactobacillus LP-Onlly is in institute
Stating the parts by weight in composition is preferably 3~5 parts.Lactobacillus plantarum (Lactobacillus plantarum) of the present invention
LP-Onlly is deposited in China Committee for Culture Collection of Microorganisms's common micro-organisms center, ground on December 06th, 2004
Location is Yard 1, BeiChen xi Road, Chaoyang District, Beijing City 3, and Institute of Microorganism, Academia Sinica, biological deposits number is CGMCC
No.1258。
In composition of the present invention, including bifidobacterium lactis BI516, the bifidobacterium lactis BI516 is in the combination
Parts by weight in object are preferably 3~5 parts.Bifidobacterium lactis (Bifidobacterium lactis) BI516 of the present invention in
It is deposited on 01 04th, 2016 China Committee for Culture Collection of Microorganisms's common micro-organisms center, address is court, Beijing
The institute 3 of positive area's North Star West Road 1, Institute of Microorganism, Academia Sinica, biological deposits number is CGMCC No.11959.
In composition of the present invention, including bifidobacterium longum BL88-Onlly, the bifidobacterium longum BL88-Onlly
Parts by weight in the composition are preferably 3~5 parts.Bifidobacterium longum (Bifidobacterium of the present invention
Longum) BL88-Onlly was deposited in China Committee for Culture Collection of Microorganisms's commonly micro- life on 07 13rd, 2007
Object center, address are Yard 1, BeiChen xi Road, Chaoyang District, Beijing City 3, Institute of Microorganism, Academia Sinica, biological deposits number
For CGMCC No.2107.
In the present invention, the plant lactobacillus LP-Onlly, bifidobacterium lactis and bifidobacterium longum BL88-Onlly can
Promote vitamin D synthesis by number of mechanisms, improve minerals availability, increase calcium level, increases bone density and bone mine contains
Amount, and the strain activity is high, stability is strong, can play booster action to promotion calcium uptake.
In composition of the present invention, including aminoglucose hydrochloride, the aminoglucose hydrochloride is in the composition
In parts by weight be preferably 25~35 parts.Aminoglucose hydrochloride of the present invention can reduce osteoarthritis or rheumatic arthritis
The symptoms such as caused arthroncus, anchylosis, and substantially improve the quality of life of arthritic.The present invention is to the hydrochloric acid
There is no particular determinations in the source of Glucosamine, utilize the conventional reagent of this field.
In composition of the present invention, including newborn mineral salt, the parts by weight of the mineral salt in the composition are preferred
It is 30~40 parts.Cream mineral salt of the present invention is preferably milk calcium.Cream mineral salt of the present invention is new resource food, with whey
It for raw material, is removed the ingredients such as protein, lactose and is made, calcium content is 23~28%, and containing identical as skeleton ratio
Other microelements such as phosphorus, magnesium and potassium iron zinc-copper, have protective effect to bone.Source of the present invention to the newborn mineral salt
There is no particular determinations, utilize the conventional reagent of this field.
In composition of the present invention, including oligosaccharide, the parts by weight of the oligosaccharide in the composition are preferably 5
~8 parts.Oligosaccharide of the present invention preferably includes: in oligofructose, xylo-oligosaccharide, oligoisomaltose and galactooligosaccharide
One or more mixing.Oligosaccharide of the present invention can be used as the proliferation factor of beneficial bacterium in enteron aisle, especially to Bifidobacterium
Cultivation effect is obvious；And Bifidobacterium is with health role to human body, such as improves vitamin metabolism, wherein generation of vitamin D, K
It thanks to the metabolism with calcium to be closely related.
In composition of the present invention, including casein phosphopeptide, the casein phosphopeptide is in the composition
Parts by weight are preferably 3~7 parts.Casein phosphopeptide of the present invention is pure by enzyme hydrolysis, separation using bovine casein as raw material
Change obtained biologically active peptide, there is chelated calcium ability.It can be with the divalent minerals such as calcium, iron, magnesium, zinc, selenium in small intestine condition
Matter ions binding prevents calcium phosphate precipitation, enhances the concentration of enteral dissolvable mine substance, to promote to be absorbed and utilized.This
Inventing the casein phosphopeptide in the composition can protect in binding transport calcium, the short-distance transport for being equivalent to calcium in small intestine
Tool avoids calcium from being lost during circulation, promotes the absorption and utilization of calcium.
In composition of the present invention, including auxiliary material, the parts by weight of the auxiliary material in the composition are preferably 4.5~
9 parts.Auxiliary material of the present invention preferably includes: maltodextrin, starch, lactose, DEXTROSE ANHYDROUS, magnesium stearate and hypromellose
One of element or a variety of mixing.Auxiliary material of the present invention can be used for adjusting in the composition each component filling and
The adhesiveness of material, mobility etc. when tabletting, if hydroxypropyl methylcellulose is tablet premix coating material.
The present invention also provides application of the above-mentioned composition in the food that preparation increases bone density.Food of the present invention
Dosage form be preferably tablet, capsule or pulvis.There is no particular determinations for preparation method of the present invention to the food, utilize ability
The customary preparation methods in domain.
The present invention also provides application of the above-mentioned composition in the drug that preparation increases bone density.Drug of the present invention
Dosage form be preferably tablet, capsule or pulvis.There is no particular determinations for preparation method of the present invention to the drug, utilize ability
The customary preparation methods in domain.
The present invention also provides application of the above-mentioned composition in the health care product that preparation increases bone density.Guarantor of the present invention
The dosage form of strong product is preferably tablet, capsule or pulvis.There is no particular determination, benefits for preparation method of the present invention to the health care product
With the customary preparation methods of this field.
The present invention also provides application of the above-mentioned composition in the food that preparation promotes calcium uptake.Invent the food
Dosage form is preferably tablet, capsule or pulvis.There is no particular determinations for preparation method of the present invention to the food, utilize this field
Customary preparation methods.
The present invention also provides application of the above-mentioned composition in the drug that preparation promotes calcium uptake.Invent the drug
Dosage form is preferably tablet, capsule or pulvis.There is no particular determinations for preparation method of the present invention to the drug, utilize this field
Customary preparation methods.
The present invention also provides application of the above-mentioned composition in the health care product that preparation promotes calcium uptake.Invent the health care
The dosage form of product is preferably tablet, capsule or pulvis.There is no particular determinations for preparation method of the present invention to the health care product, utilize
The customary preparation methods of this field.
It is closed below with reference to embodiment to the composition of probiotics provided by the invention and aminoglucose hydrochloride and its in bone
The application of section health aspect is described in detail, but they cannot be interpreted as limiting the scope of the present invention.
Embodiment 1
Each component is re-dubbed composition according to following weight: plant lactobacillus LP-Onlly 2kg, bifidobacterium lactis
BI516 5kg, bifidobacterium longum BL88-Onlly 2kg, aminoglucose hydrochloride 40kg, newborn mineral salt 40kg, oligofructose
1kg, casein phosphopeptide 4kg, maltodextrin 5.5kg, magnesium stearate 0.5kg.
The composition of the probiotics and aminoglucose hydrochloride that are prepared using embodiment 1 carries out following experiment as sample:
Experiment 1: increase bone density experiment
Sample and material: object is closed as sample using example 1 group, the composition human body recommended amounts are daily 3.78g/ days
60kg.Sample calcium content is 11.3%.70 female adult rats of this experimental selection (cleaning grade SD rat), 250~288g.
20~25 DEG C of room temperature of raising, relative humidity 40~70%.
The Nembutal sodium solution that 30mg/kgbw is injected intraperitoneally in rat is anaesthetized, and unhairing at the costovertebral angle of back is used respectively
The tincture of iodine and alcohol disinfecting cut off bilateral ovaries, separately take the identical operation of one group of animal row but do not cut off bilateral ovaries, as sham-operation
Control group.5 days after rat ovary excision, vaginal smear examination is carried out, ovary is rejected and cuts off incomplete rat.
Dose design: requiring according to experimental project, if basic, normal, high three dosage groups, i.e., 0.32,0.63,1.89g/kg
Bw, is equivalent to 5 times of human body recommended dose, and 10 times, 30 times.Rat after above-mentioned operation is randomly divided into model comparison according to weight
Group, positive controls (estradiol of 1.0mg/kgbw), calcium carbonate control group (calcium level is identical as high dose calcium level) with
And basic, normal, high three dosage groups, every group 10, separately take 10 sham-operation rats as Sham-operated control group.
Tested material is prepared: separately sampled product 0.32,0.63,1.89g add deionized water to 10mL, uniformly prepare it is low, in,
The test liquid of high dose group；Calcium carbonate 534mg is taken, adds deionized water to 10mL, uniform mixed preparing calcium carbonate control group is for examination
Liquid；Sham-operation group and model control group give deionized water.Each group drinking water is deionized water.
Tested material gives mode: to sample, stomach-filling volume is 10mL/kg weight for stomach-filling.Daily stomach-filling is primary, and each group dosage is set
It counts to sample 12 weeks, rat drinks deionized water during entire experiment, records weight weekly, and during this period, rat feed is used in test
Formula is as shown in table 1:
Table 1 refers to feed formula
The every kg mixed mineral salt of note 1. contains (g): potassium dihydrogen phosphate, and 250.0；Sodium chloride, 74.0；Potassium sulfate, 46.6；Chinese holly
Rafter acid potassium (single crystals water) 28.0；Magnesia 24.0；Citron ferrous acid, 6.06；Zinc carbonate, 1.65；Manganese carbonate, 0.63；Copper carbonate
0.30；Potassium iodide, 0.01；Sodium selenate, 0.01025；To amine molybdate, 0.00795；Sodium metasilicate (9 crystallizations water), 1.45；Sulphur
Sour potassium chromium (12 crystallizations water), 0.275；Boric acid, 0.0815；Sodium fluoride, 0.0635；Nickelous carbonate, 0.318；Lithium chloride 0.0174；
Ammonium vanadate, 0.0066；Add sucrose to 1kg.
2. every kg mixed vitamin contains (g): niacin, 3.0；Calcium pantothenate, 1.6；Puridoxine hydrochloride, 0.7；Thiamine hydrochloride
Element, 0.60；Vitamin B2,0.60；Folic acid, 0.2；Biotin, 0.02；Vitamin B12,2.5；Vitamin E, 15.0；Vitamin
A, 0.8；Vitamine D3,0.25；Vitamin K, 0.075；Sucrose 974.655.
Measuring influence of the composition to rat body weight described in embodiment 1, the results are shown in Table 2:
Influence of 2 sample of table to rat body weight
Note: * indicates that the group difference compared with model control group of each group in same row has conspicuousness, P < 0.05
As can be seen from Table 2, the rear surrounding average weight of model control group and weight gain are all remarkably higher than Sham-operated control group, prompt
Female hormone reduction causes hormonal readiness disorder to lead to weight abnormal growth to possible animal after surgery, illustrates that model is set up.Sun
Property the middle surrounding average weight of control group, rear surrounding average weight, weight gain be substantially less than castration model control group.Each dosage group
Compared with model control group, original body mass, every four weeks average weight and weight gain are without obvious significant difference (P > 0.05).High dose
Group is with calcium carbonate control group compared with, original body mass, every four weeks average weight and there are no significant the difference (P > 0.05) of increasing weight.
Femoral bmd measurement: dissection rat removes left femur, femur is dried to constant weight.Using discovery-
Wi type borne densitometers measure rat femur midpoint and femur distal end bone density, while being contained using aas determination bone calcium
Amount, the results are shown in Table 3:
Influence of 3 sample of table to the weight, bone calcium and femoral bmd of rat stock weight
Note: * indicates that the group difference compared with model control group of each group in same row has conspicuousness (P < 0.05)
Seen from table 3, the indices of positive controls and Sham-operated control group in addition to femur dry weight, are all remarkably higher than mould
Type control group.Compared with model control group, the femur distal end bone density of high dose group and calcium carbonate control group, calcium content of bone are equal
Obviously increase, high dose group is compared with the calcium carbonate control group of identical calcium level, indices there are no significant difference (P >
0.05)。
Under this experiment condition, model control group calcium content of bone, bone density value are substantially less than sham-operation group and the positive is right
According to group；Tested material group high dose group calcium content of bone, femur distal end bone density value are all remarkably higher than model control group, it is believed that
The composition, which has rat, increases bone density function.
Experiment 2: calcium uptake experiment
Sample and material: using composition in embodiment 1 as sample, the composition human body recommended amounts are daily 3.78g/ days
60kg.Sample calcium content is 11.3%.The ablactation rat (cleaning grade SD rat) of birth 4 weeks, 60~79g, 50.Raise room temperature
20~25 DEG C of degree, relative humidity 40~70%.
Dose design: setting basic, normal, high three dosage groups, i.e., 0.32,0.63,1.89g/kgbw are equivalent to human body recommendation
5 times of dosage, 10 times, 30 times.A low calcium control group and calcium carbonate control group (calcium level and a high dose calcium are set up simultaneously
It is horizontal identical).
Tested material is prepared: separately sampled product 0.32,0.63,1.89g add deionized water to 10mL, uniformly prepare it is low, in,
The test liquid of high dose group；Calcium carbonate 534mg is taken, adds deionized water to 10mL, uniform mixed preparing calcium carbonate control group is for examination
Liquid.Each group drinking water is deionized water.
Tested material gives mode: to sample, stomach-filling volume is 10mL/kg weight for stomach-filling.
Calcium uptake experimental method
A sample collection:
The ablactation rat sub-cage rearing of birth 4 weeks.According to weight be randomly divided into low calcium control group, calcium carbonate control group, with
And basic, normal, high three dosage groups, every group of 10 rats.Each group sample is given in stomach-filling, and low calcium control group gives deionized water, and totally 4
Week.It is primary that height, weight are measured weekly.Calcium metabolism experiment in 3 days is carried out after testing 3 weeks.3 days food rations are recorded, are collected 72 hours
Excrement measures the calcium content in excrement.Mouse excrement sample is dried in 80 DEG C of baking ovens, sets fine grinding after cooling in drier.Pay attention to anti-
The only pollution in sample preparation procedure.During this period, test is as shown in table 4 with the feed formula of mouse:
4 basal feed formula of table (adjustment Ca2+For 150mg/100g feed)
The every kg mixed mineral salt of note 1. contains (g): potassium dihydrogen phosphate,；Sodium chloride, 74.0；Magnesium carbonate, 50.2；Lactic acid is sub-
Iron, 5.4；Zinc lactate 4.16；Manganese carbonate, 3.5；Salzburg vitriol, 0.605；Sodium selenate, 0.0066；Potassium iodide, 0.00776；
Six hydrated chromium trichlorides 0.292；Add sucrose to 1kg.
2. every kg mixed vitamin contains (g): vitamin A, 400,000IU；Vitamine D3；100,000IU；Vitamin E,
500IU；Vitamin K, 5mg；Vitamin B1,600mg；Vitamin B2,600mg；Vitamin B6,700mg；Vitamin B12,1mg；
Niacin, 3g；Folic acid, 200mg；Calcium pantothenate, 1.6g；Biotin, 20mg；Add sucrose to 1kg.
B calcium content of bone measurement: aas determination.
The apparent absorptivity of c calcium:
It takes in calcium (mg)=feed calcium content (mg/g) × 3 day feed consumption+sample and takes in calcium content
Calcium content (mg/g) × 3 day stool output in excrement calcium (mg)=excrement
The apparent absorptivity (%) of calcium=(intake calcium-excrement calcium)/intake calcium × 100%
Experimental result is as shown in table 5:
Influence of 5 sample of table to calcium uptake in rat experiment periods
Note: * indicates that the group difference compared with model control group of each group in same row has conspicuousness (P < 0.05)
By table 5 as it can be seen that the weight of each dosage group, height compared with low calcium control group without obvious sex differernce (P > 0.05).
The apparent absorptivity of high dose group calcium is significantly higher than low calcium control group.
Embodiment 2
Each component is re-dubbed composition according to following weight ratio: plant lactobacillus LP-Onlly 3kg, bifidobacterium lactis
BI516 5kg, bifidobacterium longum BL88-Onlly 5kg, aminoglucose hydrochloride 35kg, newborn mineral salt 40kg, xylo-oligosaccharide
6kg, casein phosphopeptide 4kg, DEXTROSE ANHYDROUS 2kg.
It is real to carry out the experiment of increase bone density and calcium uptake in the same manner as in Example 1 for the composition obtained using embodiment 2
It tests, wherein influence of the sample to rat body weight is as shown in table 6:
Influence of 6 sample of table to rat body weight
Note: * indicates that the group difference compared with model control group of each group in same row has conspicuousness, P < 0.05
By table 6 as it can be seen that the middle surrounding of model control group, rear surrounding average weight and weight gain are all remarkably higher than sham-operation control
Group, prompting possible animal, female hormone reduction causes hormonal readiness disorder to lead to weight abnormal growth after surgery, illustrates model
It sets up.The middle surrounding average weight of positive controls, rear surrounding average weight, weight gain are substantially less than castration model control group.
Each dosage group compared with model control group, original body mass, every four weeks average weight and weight gain without obvious significant difference (P >
0.05).High dose group is compared with calcium carbonate control group, original body mass, every four weeks average weight and weight gain there are no significant difference
(P>0.05)。
The results are shown in Table 7 for influence of the sample to the weight of rat stock weight, bone calcium and femoral bmd:
Influence of 7 sample of table to the weight, bone calcium and femoral bmd of rat stock weight
Note: * indicates that the group difference compared with model control group of each group in same row has conspicuousness (P < 0.05)
By table 7 as it can be seen that the indices of positive controls and Sham-operated control group in addition to femur dry weight, are all remarkably higher than mould
Type control group.Compared with model control group, the femur distal end bone density of high dose group and calcium carbonate control group, calcium content of bone are equal
Obviously increase, high dose group is compared with the calcium carbonate control group of identical calcium level, indices there are no significant difference (P >
0.05)。
Under this experiment condition, model control group calcium content of bone, bone density value are substantially less than sham-operation group and the positive is right
According to group；Tested material group high dose group calcium content of bone, femur distal end bone density value are all remarkably higher than model control group, it is believed that
The composition, which has rat, increases bone density function.
Calcium uptake experimental result is as shown in table 8:
Influence of 8 sample of table to calcium uptake in rat experiment periods
Note: * indicates that the group difference compared with model control group of each group in same row has conspicuousness (P < 0.05)
By table 8 as it can be seen that the weight of each dosage group, height compared with low calcium control group without obvious sex differernce (P > 0.05).
Middle dosage, high dose group calcium apparent absorptivity be significantly higher than low calcium control group.
Embodiment 3
Each component is re-dubbed composition according to following weight ratio: plant lactobacillus LP-Onlly 4kg, bifidobacterium lactis
BI516 3kg, bifidobacterium longum BL88-Onlly 2kg, aminoglucose hydrochloride 25kg, newborn mineral salt 40kg, xylo-oligosaccharide
7kg, casein phosphopeptide 10kg, DEXTROSE ANHYDROUS 5kg, maltodextrin 4kg.
It is real to carry out the experiment of increase bone density and calcium uptake same as Example 1 for the composition obtained using embodiment 3
It tests, wherein sample influences rat body weight as shown in table 9:
Influence of 9 sample of table to rat body weight
Note: * indicates that the group difference compared with model control group of each group in same row has conspicuousness, P < 0.05
By table 9 as it can be seen that the middle surrounding of model control group, rear surrounding average weight and weight gain are all remarkably higher than sham-operation control
Group, prompting possible animal, female hormone reduction causes hormonal readiness disorder to lead to weight abnormal growth after surgery, illustrates model
It sets up.The middle surrounding average weight of positive controls, rear surrounding average weight, weight gain are substantially less than castration model control group.
Each dosage group compared with model control group, original body mass, every four weeks average weight and weight gain without obvious significant difference (P >
0.05).High dose group is compared with calcium carbonate control group, original body mass, every four weeks average weight and weight gain there are no significant difference
(P>0.05)。
The results are shown in Table 10 for influence of the sample to the weight of rat stock weight, bone calcium and femoral bmd:
Influence of 10 sample of table to the weight, bone calcium and femoral bmd of rat stock weight
Note: * indicates that the group difference compared with model control group of each group in same row has conspicuousness (P < 0.05)
By table 10 as it can be seen that the indices of positive controls and Sham-operated control group in addition to femur dry weight, are all remarkably higher than
Model control group.Compared with model control group, the femur distal end bone density of high dose group and calcium carbonate control group, calcium content of bone
Obviously increase, high dose group is compared with the calcium carbonate control group of identical calcium level, indices there are no significant difference
(P>0.05)。
Under this experiment condition, model control group calcium content of bone, bone density value are substantially less than sham-operation group and the positive is right
According to group；Tested material group high dose group calcium content of bone, femur distal end bone density value are all remarkably higher than model control group, it is believed that
The composition, which has rat, increases bone density function.
Calcium uptake experimental result is as shown in table 11:
Influence of 11 sample of table to calcium uptake in rat experiment periods
Note: * indicates that the group difference compared with model control group of each group in same row has conspicuousness (P < 0.05)
By table 11 as it can be seen that the weight of each dosage group, height compared with low calcium control group without obvious sex differernce (P > 0.05).
The apparent absorptivity of high dose group calcium is significantly higher than low calcium control group.
In conclusion having increase bone close the present invention provides the composition of a kind of probiotics and aminoglucose hydrochloride
Degree, the function of promoting calcium absorptivity can be used for making corresponding food or drug or health care product in terms of bony articulation health.
The above is only a preferred embodiment of the present invention, it is noted that for the ordinary skill people of the art
For member, various improvements and modifications may be made without departing from the principle of the present invention, these improvements and modifications are also answered
It is considered as protection scope of the present invention.
Claims (10)
1. the composition of a kind of probiotics and aminoglucose hydrochloride, which is characterized in that comprise the following components in parts by weight: plant
1~5 part of lactobacillus LP-Onlly, 1~5 part of bifidobacterium lactis BI516,1~5 part of bifidobacterium longum BL88-Onlly, hydrochloric acid
20~40 parts of Glucosamine, 20~40 parts of newborn mineral salt, 1~10 part and 1~10 part of casein phosphopeptide of oligosaccharide.
2. composition according to claim 1, which is characterized in that the oligosaccharide includes: oligofructose, xylo-oligosaccharide, low
One of polyisomaltose and galactooligosaccharide or a variety of mixing.
3. composition according to claim 1, which is characterized in that it further include auxiliary material in the composition, the weight of the auxiliary material
Measuring number is 2~9 parts.
4. composition according to claim 3, which is characterized in that the auxiliary material includes: maltodextrin, starch, lactose, anhydrous
One of glucose, magnesium stearate and hydroxypropyl methylcellulose or a variety of mixing.
5. application of any one of Claims 1 to 4 composition in the food that preparation increases bone density.
6. application of any one of Claims 1 to 4 composition in the drug that preparation increases bone density.
7. application of any one of Claims 1 to 4 composition in the health care product that preparation increases bone density.
8. application of any one of Claims 1 to 4 composition in the food that preparation promotes calcium uptake.
9. application of any one of Claims 1 to 4 composition in the drug that preparation promotes calcium uptake.
10. application of any one of Claims 1 to 4 composition in the health care product that preparation promotes calcium uptake.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811594602.9A CN109432388B (en) | 2018-12-25 | 2018-12-25 | Composition of probiotics and glucosamine hydrochloride and application of composition in bone joint health |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811594602.9A CN109432388B (en) | 2018-12-25 | 2018-12-25 | Composition of probiotics and glucosamine hydrochloride and application of composition in bone joint health |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN109432388A true CN109432388A (en) | 2019-03-08 |
| CN109432388B CN109432388B (en) | 2021-12-31 |
Family
ID=65535638
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811594602.9A Active CN109432388B (en) | 2018-12-25 | 2018-12-25 | Composition of probiotics and glucosamine hydrochloride and application of composition in bone joint health |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109432388B (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114196603A (en) * | 2022-01-25 | 2022-03-18 | 山东向日葵生物工程有限公司 | Bifidobacterium lactis SF-B21 and application thereof in preparing fermented beverage for increasing bone density |
| CN114634901A (en) * | 2022-05-18 | 2022-06-17 | 微康益生菌(苏州)股份有限公司 | Lactobacillus casei LC16 for promoting bone health and culture method and application thereof |
| CN115948296A (en) * | 2022-12-23 | 2023-04-11 | 四川高福记生物科技有限公司 | Lactobacillus plantarum for improving muscle and bone health and/or improving athletic ability, and composition and application thereof |
| CN116195742A (en) * | 2021-11-30 | 2023-06-02 | 内蒙古伊利实业集团股份有限公司 | Application of bifidobacterium lactis BL-99 in cartilage protection |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102423035A (en) * | 2011-11-25 | 2012-04-25 | 苏州先阔生物科技有限公司 | Health care food containing xylo-oligosaccharides for assisting in treating quinquagenarian retrogressive bone joint diseases |
| CN103446577A (en) * | 2013-09-03 | 2013-12-18 | 庞会心 | Medicine composition for preventing and treating arthritis and application thereof |
| CN105166938A (en) * | 2015-08-11 | 2015-12-23 | 湖南科尔生物技术有限公司 | Casein and bone protocalcium compound probiotic preparation |
| CN106107980A (en) * | 2016-06-28 | 2016-11-16 | 张标 | A kind of can put on weight, height, calcium content of bone and the osteoarthrosis health product of raising bone density |
| CN106174045A (en) * | 2016-07-25 | 2016-12-07 | 三株福尔制药有限公司 | A kind of probiotics fermention calcium-supplementing preparation and preparation method thereof |
| CN106421757A (en) * | 2016-09-09 | 2017-02-22 | 杨森健 | Composition for assisting in treating gout and increasing bone density and application of composition |
| CN106880040A (en) * | 2017-04-11 | 2017-06-23 | 姜红成 | Prepare the fermentation composition and preparation method with the plant enzyme suitable for the conditioning maintenance of rheumatism osteoarthritis patients |
-
2018
- 2018-12-25 CN CN201811594602.9A patent/CN109432388B/en active Active
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102423035A (en) * | 2011-11-25 | 2012-04-25 | 苏州先阔生物科技有限公司 | Health care food containing xylo-oligosaccharides for assisting in treating quinquagenarian retrogressive bone joint diseases |
| CN103446577A (en) * | 2013-09-03 | 2013-12-18 | 庞会心 | Medicine composition for preventing and treating arthritis and application thereof |
| CN105166938A (en) * | 2015-08-11 | 2015-12-23 | 湖南科尔生物技术有限公司 | Casein and bone protocalcium compound probiotic preparation |
| CN106107980A (en) * | 2016-06-28 | 2016-11-16 | 张标 | A kind of can put on weight, height, calcium content of bone and the osteoarthrosis health product of raising bone density |
| CN106174045A (en) * | 2016-07-25 | 2016-12-07 | 三株福尔制药有限公司 | A kind of probiotics fermention calcium-supplementing preparation and preparation method thereof |
| CN106421757A (en) * | 2016-09-09 | 2017-02-22 | 杨森健 | Composition for assisting in treating gout and increasing bone density and application of composition |
| CN106880040A (en) * | 2017-04-11 | 2017-06-23 | 姜红成 | Prepare the fermentation composition and preparation method with the plant enzyme suitable for the conditioning maintenance of rheumatism osteoarthritis patients |
Non-Patent Citations (3)
| Title |
|---|
| 张颜廷等: "益生菌制剂对钙缺乏骨质疏松症的防治作用", 《中国骨质疏松杂志》 * |
| 李哲等: "氨基葡萄糖对绝经后骨质疏松模型大鼠的保护作用", 《中国海洋药物》 * |
| 李路娇等: "肠道菌群与骨骼代谢", 《中华骨质疏松和骨矿盐疾病杂志》 * |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116195742A (en) * | 2021-11-30 | 2023-06-02 | 内蒙古伊利实业集团股份有限公司 | Application of bifidobacterium lactis BL-99 in cartilage protection |
| CN116195742B (en) * | 2021-11-30 | 2024-07-09 | 内蒙古伊利实业集团股份有限公司 | Application of bifidobacterium lactis BL-99 in cartilage protection |
| CN114196603A (en) * | 2022-01-25 | 2022-03-18 | 山东向日葵生物工程有限公司 | Bifidobacterium lactis SF-B21 and application thereof in preparing fermented beverage for increasing bone density |
| CN114196603B (en) * | 2022-01-25 | 2024-05-24 | 山东向日葵生物工程有限公司 | Bifidobacterium lactis SF-B21 and application thereof in preparation of bone mineral density increasing fermented beverage |
| CN114634901A (en) * | 2022-05-18 | 2022-06-17 | 微康益生菌(苏州)股份有限公司 | Lactobacillus casei LC16 for promoting bone health and culture method and application thereof |
| CN114634901B (en) * | 2022-05-18 | 2022-08-30 | 微康益生菌(苏州)股份有限公司 | Lactobacillus casei LC16 for promoting bone health and culture method and application thereof |
| CN115948296A (en) * | 2022-12-23 | 2023-04-11 | 四川高福记生物科技有限公司 | Lactobacillus plantarum for improving muscle and bone health and/or improving athletic ability, and composition and application thereof |
| CN115948296B (en) * | 2022-12-23 | 2024-02-27 | 四川高福记生物科技有限公司 | Lactobacillus plantarum for improving musculoskeletal health and/or improving exercise capacity, and composition and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN109432388B (en) | 2021-12-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109432388A (en) | The composition and its application in terms of bony articulation health of a kind of probiotics and aminoglucose hydrochloride | |
| CN102318835B (en) | Composition for reducing bone loss and preparation method thereof | |
| Yokel et al. | Aluminum bioavailability from the approved food additive leavening agent acidic sodium aluminum phosphate, incorporated into a baked good, is lower than from water | |
| CN105145846A (en) | Nutritional bag for increasing bone density and improving osteoporosis | |
| CN106135890A (en) | A kind of alimentation composition contributing to bony articulation health | |
| CN104188999A (en) | Composition capable of increasing bone density and improving functions of skeletons and joints and preparation method thereof | |
| CN102423487B (en) | Osteoarticular health-care composition and its application | |
| CN106235311A (en) | A kind of compositions promoting skeletal system health and application thereof | |
| CN105056216A (en) | Calcium supplementing preparation/granule and preparation method thereof | |
| CN109984269A (en) | It is a kind of with the pet nutrition cream and preparation method of replenishing the calcium and keep articulation health | |
| CN102160614A (en) | Compound preparation for improving immunity of human bodies and enhancing bone density and application thereof | |
| CN103458876A (en) | Galenic composition suitable for administration to a non-human animal, uses thereof, and associated methods | |
| US8192734B2 (en) | Compositions and methods for bone strengthening | |
| CN103719282A (en) | Formula milk powder for middle-aged and elderly people | |
| CN103141892B (en) | Cucumber seed beverage and preparation method and application thereof | |
| CN106213492A (en) | A kind of lifter motion function also increases health-oriented products and the preparation method of bone density | |
| CN108576816A (en) | A kind of composition increasing bone density | |
| Dolphin et al. | Maternal diets, nutritional status, and zinc in contemporary Mexican infants' teeth: Implications for reconstructing paleodiets | |
| CN116875515B (en) | Lactobacillus paracasei GF027 for improving memory and children growth and application thereof | |
| CN103211972B (en) | A kind of kidney-tonifying composition and preparation method thereof | |
| Ross et al. | Overview of calcium | |
| CN107969649A (en) | One kind is replenished the calcium composition and preparation method | |
| CN105194657A (en) | Preparation for increasing bone density and preparation method thereof | |
| CN101268836B (en) | Nutrition high calcium medicinal granule and preparing technique | |
| CN108968075A (en) | It is a kind of improve bone health composition and its application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |